

1. Record Nr.	UNINA9910635395003321
Titolo	Cancer nanotechnology // Angela Maria Almeida de Sousa, Christiane Pienna Soares, and Marlus Chorilli, editors
Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2023] ©2023
ISBN	3-031-17831-9
Descrizione fisica	1 online resource (386 pages)
Disciplina	616.99406
Soggetti	Cancer - Treatment - Technological innovations Nanomedicine Nanotechnology Neoplasm - therapy
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Intro -- Preface -- Contents -- Part I: Materials for Cancer Nanotechnology -- Lipid Nanocarriers for Breast Cancer Treatment -- 1 Introduction -- 2 Properties and Advantages of Lipid Nanocarriers for Breast Cancer Management -- 3 Lipid-Based Nanocarriers for Breast Cancer: Approved and Under Development -- 4 Nanocarriers for Parenteral Administration -- 4.1 Liposomes -- 4.1.1 Co-encapsulation of Drugs -- 4.1.2 Long-Circulating Liposomes -- 4.1.3 Stimulus-Responsive Liposomes -- 4.1.4 Ligand-Targeted Liposome -- 4.1.5 Liposome-Based Gene Therapy -- 4.1.6 Liposomes for Theranostics -- 4.2 Solid Lipid Nanoparticles and Nanostructured Lipid Carriers -- 4.3 Nanoemulsions and Microemulsions -- 4.4 Liquid Crystalline Phases -- 5 Nanocarriers for Oral Administration -- 5.1 Liposomes -- 5.2 Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) -- 5.3 Micro- and Nanoemulsions -- 5.4 Liquid Crystalline Nanoparticles (LCNPs) -- 6 Nanocarriers for Localized Treatment -- 6.1 Intraductal Therapy -- 6.1.1 Liposomes -- 6.1.2 Nanoemulsions -- 6.2 Topical-Transdermal Therapy -- 6.2.1 Vesicles -- 6.2.2 Micro- and Nanoemulsions -- 6.2.3 Lipid Nanoparticles -- 6.2.4 Liquid Crystalline Nanoparticles -- 6.3 Subcutaneous Delivery --

6.3.1 Microemulsions -- 6.3.2 Solid Lipid Nanoparticles -- 7
Conclusions -- References -- Polymeric Nanocarriers in Cancer
Theranostics -- 1 Introduction -- 2 Nanostructured Carriers
and Cancer Treatment -- 3 Photodynamic (PDT) and Photothermal (PTT)
Cancer Therapies -- 3.1 Photodynamic Therapy (PDT) -- 3.2
Photothermal Therapy (PTT) -- 4 Imaging Agents and Techniques
in Cancer Theranostics -- 5 Fluorophores as Photosensitizers
in Theranostics -- 6 Polymeric Nanoparticles as Nanotheranostics -- 7
Inorganic-Based Probes in Polymeric Nanoparticles for Imaging.
8 Polymeric Nanoparticles with Organic Fluorescent Tracers
and Photosensitizers -- 9 Concluding Remarks -- References --
Functionalization of Nanosystems in Cancer Treatment -- 1
Introduction -- 2 Strategies for Functionalization of Nanostructures --
2.1 Non-covalent Functionalization -- 2.2 Covalent Functionalization
-- 2.2.1 Carbodiimide Chemistry -- 2.2.2 Maleimide Chemistry --
2.2.3 Click Chemistry -- 3 Active Targeting Strategies -- 3.1 Proteins
-- 3.2 Peptides -- 3.3 Small Molecules -- 4 Conclusion and Future
Perspectives -- References -- 3D Bioprinting for Cancer Models -- 1
Introduction -- 2 Tumor Microenvironment Multicellularity -- 3
Bioprinting Living and Non-living Entities for Functional Organotypic
Models -- 3.1 Breast Cancer -- 3.2 Ovarian Cancer -- 3.3 Pancreatic
Cancer -- 3.4 Brain Cancer -- 3.5 Hepatic Cancer -- 4 Current
Limitations in 3D Bioprinting -- 5 Conclusion and Future Perspectives
-- References -- Monoclonal Antibodies in Nanosystems as a Strategy
for Cancer Treatment -- 1 Introduction -- 2 Monoclonal Antibodies
in Cancer Therapy (mAbs) -- 2.1 Antibody Structure -- 2.2
Biotechnological Synthesis Techniques -- 2.2.1 Hybridoma -- 2.2.2
Transgenic Mouse -- 2.2.3 Phage Display -- 2.3 Engineered
Therapeutic mAbs -- 2.3.1 Chimeric mAbs -- 2.3.2 Humanized mAbs
-- 2.3.3 Human mAbs -- 2.3.4 Bispecific mAbs -- 2.4 Therapeutic
Applications of mAbs in Cancer Therapy -- 2.4.1 Blocking Cell
Signaling -- 2.4.2 Antibody-Dependent Cellular Cytotoxicity (ADCC) --
2.4.3 Antibody-Mediated Complement-Dependent Cytotoxicity (CDC)
-- 2.4.4 Cancer Immunotherapy -- 2.4.5 Antibody-Drug Conjugate
(ADC) -- 3 Functionalization Strategies -- 3.1 Non-covalent Methods
-- 3.1.1 Adsorption -- 3.1.2 Avidin-Biotin System -- 3.2 Covalent
Bonding -- 3.2.1 Carbodiimide Chemistry -- 3.2.2 Maleimide
Chemistry -- 3.2.3 Click Chemistry.
3.2.4 Other Covalent Methodologies -- 4 Nanoparticles Functionalized
with Antibodies -- 4.1 Lipid Nanoparticles -- 4.1.1 Liposomes -- 4.1.2
Solid Lipid Nanoparticles and Nanostructured Lipid Carriers -- 4.2
Polymeric Nanoparticles -- 4.3 Inorganic Nanoparticles -- 4.3.1 Iron --
4.3.2 Gold -- 4.3.3 Silica -- 4.3.4 Quantum Dots -- 5 Conclusion --
References -- Part II: Strategies for Cancer Therapy Through
Nanotechnology -- Nanotechnology to Correct Mitochondrial Disorders
in Cancer Diseases -- 1 Introduction -- 2 The Mitochondrial Genome
-- 2.1 Mitochondrial Genes -- 2.2 Mitochondrial Gene Mutations
and Mitochondrial DNA Diseases -- 2.3 Mutations of the Mitochondrial
ND1 Gene and Associated Diseases -- 2.4 Mitochondria
as a Therapeutic Target in Cancer -- 3 Mitochondrial Gene Therapy --
3.1 Mitochondrial Gene/Protein Expression and Mitochondria Targeting
Using Nanotechnology -- 3.1.1 Mitochondrial Gene/Protein Expression
-- 3.1.2 Mitochondrial-Targeted Delivery Systems -- 3.1.3
Mitochondria-Targeted Peptide Delivery Systems -- 3.2 Future
Challenges -- References -- Chronobiology and Nanotechnology
for Personalized Cancer Therapy -- 1 Mammalian Circadian Clock -- 2
Circadian Disruption and Cancer Development -- 3 Chronotherapy
for Cancer Treatment -- 4 Nanotechnology Applied for Cancer

Treatment -- 5 Chronotherapy and Nanotechnology -- 6 Conclusions -- References -- The Function of DNA and RNA Nanovaccines in the Treatment of Cancer -- 1 Introduction -- 2 Vaccine in Treatment and Prevention -- 3 Tumor Antigen -- 4 Nanovaccines Properties -- 4.1 DNA Vaccines -- 4.2 mRNA Vaccines -- 4.3 Neoantigen-Based Vaccine -- 5 Nanocarrier Design and Development: Critical Points to Induce the Immune Response -- 6 Viruslike Particles as a Nanocarrier -- 7 Conclusion -- References -- Messenger RNA Nanovaccine in Cancer Immunotherapy -- 1 Introduction. 2 mRNA Modification -- 2.1 5 Cap -- 2.2 UTRs -- 2.3 Poly(A) Tail -- 2.4 Nucleotide Modification -- 3 mRNA Delivery System -- 3.1 Protamine-Based Technology -- 3.2 Polymer Carrier Technology -- 3.3 Lipid Nanoparticle Technology (LNP) -- 3.4 Ionizable Cationic Lipid -- 3.5 Phospholipids -- 3.6 LNP Application in COVID-19 mRNA Vaccine -- 4 Adjuvant -- 4.1 Delivery Carriers with Self-Adjuvant Properties -- 5 Antigen Selection for mRNA Cancer Vaccine -- 6 Future Directions of mRNA Cancer Vaccine -- References -- Part III: Innovative Nanotechnologies for Cancer Diagnostic and Treatment -- Nanoparticles for Therapy and Diagnostic Imaging Techniques in Cancer -- 1 Introduction -- 2 Nanoparticles for Therapy -- 2.1 Hyperthermia -- 2.1.1 Photothermal Therapy (PTT) -- 2.1.2 Gold Nanoparticles Applied in Photothermal Therapy -- 2.1.3 Photothermal Therapy and Bone Regeneration -- 2.2 Curcumin Loaded in Nanoparticles as a Therapeutic Agent -- 3 Nanomaterials Applied in Diagnostic Imaging Techniques -- 3.1 Exploring the Intrinsic Properties of Rare-Earth Elements -- 3.1.1 Luminescence of Rare-Earth Elements -- 3.1.2 Magnetic Properties of Rare-Earth Elements -- 4 Radiolabeled Nanoparticles for Treatment, Diagnosis, and Theranostics -- 4.1 Overview of Radiation in Medicine -- 4.2 Diagnosis of Cancer with Radiolabeled Multifunctional Nanomaterials -- 4.3 Radiolabeled Nanomaterials for Cancer Theranostics -- 4.4 Curcumin-Based Multifunctional Nanomaterials for Theranostic Purposes -- 4.5 Radiolabeling Techniques for Nanomaterials and Future Perspectives -- 5 Summary -- References -- Polymeric Microneedle-Based Drug Delivery Platforms for Application in Cancer Therapy -- 1 Introduction -- 2 Microneedles -- 2.1 General Structure and Properties -- 2.2 Production Techniques -- 3 Microneedles as Anticancer Vaccines -- 4 Intratumoral Administration of Therapeutics. 5 Limitations and Future Perspectives -- 6 Conclusions -- References -- Clinical Trials Involving Chemotherapy-Based Nanocarriers in Cancer Therapy: State of the Art and Future Directions -- 1 Introduction -- 2 Cancer Physiology -- 3 Nanocarriers for Drug Delivery -- 3.1 Types of Nanoparticles -- 3.1.1 Lipid-Based Nanocarriers -- 3.1.2 Polymeric Nanocarriers -- 3.1.3 Inorganic Nanocarriers -- 3.2 Mechanism of Action of Classic Chemotherapeutic Agents -- 3.3 Marketed Chemotherapy-Loaded Nanoparticles for Cancer Treatment -- 3.4 Clinical Development of Nanoparticulate Systems for Cancer Treatment -- 4 Challenges in Nanomedicine Clinical Translation -- 5 Conclusions -- References -- Index.
